Xencor (NASDAQ:XNCR) Stock: Insider Richard Ranieri Sells 81,252 Shares

Xencor, Inc. (NASDAQ:XNCR) Director Richard Ranieri sold 81,252 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $39.25, for a total transaction of $3,189,141.00. Following the sale, the director owned 18,514 shares in the company, valued at $726,674.50. This trade represents a 81.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Xencor Stock Down 2.7%

Shares of XNCR opened at $37.09 on Friday. Xencor, Inc. has a twelve month low of $10.38 and a twelve month high of $40.60. The firm’s 50 day moving average price is $27.34 and its two-hundred day moving average price is $18.10.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.83. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.28%. The company had revenue of $116.52 million during the quarter, compared to the consensus estimate of $63.00 million. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. The firm’s revenue was up 453.3% compared to the same quarter last year. On average, equities analysts forecast that Xencor, Inc. will post -2.61 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on XNCR. Wall Street Zen raised Xencor from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Bank of America lifted their target price on Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a research report on Monday, September 21st. Royal Bank Of Canada boosted their target price on Xencor from $20.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, October 27th. Barclays set a $45.00 target price on Xencor and gave the company an “overweight” rating in a research note on Monday, October 26th. Finally, Wells Fargo & Company upped their price target on Xencor from $30.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $42.22.

Institutional Investors Weigh In On Xencor

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Xencor in the second quarter valued at approximately $219,785,000. Primecap Management Co. CA acquired a new stake in shares of Xencor in the second quarter valued at approximately $163,919,000. Jefferies Financial Group Inc. boosted its stake in shares of Xencor by 189.0% during the 3rd quarter. Jefferies Financial Group Inc. now owns 2,082,243 shares of the biopharmaceutical company’s stock worth $51,952,000 after acquiring an additional 1,361,803 shares during the period. Legal & General Group Plc bought a new position in shares of Xencor during the 2nd quarter worth approximately $17,568,000. Finally, Johnson & Johnson acquired a new position in shares of Xencor during the 2nd quarter worth approximately $12,043,798.

About Xencor

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.